Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086790 | 0.86 | MEN1 (0.38) | KMT2AMEN1MAPTSMN1; SMN2HTR6 | |
| SCHEMBL3096966 | 0.86 | KIF11 (0.44) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL3085524 | 0.82 | SLC6A4 (0.42) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL3090776 | 0.82 | LTA4H (0.50) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL3084029 | 0.82 | KIF11 (0.41) | KMT2AMEN1ALDH1A1TDP1MAPT | |
| SCHEMBL7404828 | 0.76 | HTR2A (0.36) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL3381548 | 0.76 | ALDH1A1 (0.36) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL5327645 | 0.76 | ALDH1A1 (0.36) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL640081 | 0.76 | KIF11 (0.39) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL1641591 | 0.74 | ALDH1A1 (0.46) | KMT2AMEN1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0648224-A1 | CONFORMATIONALLY RESTRAINED PEPTIDE ANALOGS AS ANTIPLATELET AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-04-19 | — | — | EP | claimed |
| WO-1993024520-A1 | CONFORMATIONALLY RESTRAINED PEPTIDE ANALOGS AS ANTIPLATELET AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | claimed |
| US-11730752-B2 | Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions | NUVAMID SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20230090372-A1 | SMALL MOLECULE INHIBITORS OF VOLTAGE-GATED SODIUM CHANNEL 1.7 AND METHODS OF USING SAME | DUKE UNIVERSITY (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230060438-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-03-02 | — | — | US | disclosed |
| WO-2021119157-A1 | SMALL MOLECULE INHIBITORS OF VOLTAGE-GATED SODIUM CHANNEL 1.7 AND METHODS OF USING SAME | DUKE UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0648224-A1 | CONFORMATIONALLY RESTRAINED PEPTIDE ANALOGS AS ANTIPLATELET AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| WO-1993024520-A1 | CONFORMATIONALLY RESTRAINED PEPTIDE ANALOGS AS ANTIPLATELET AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060438-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NNT, NAMPT, NMUR1 | KMT2A 2574/4885MEN1 1575/4885CALM1 600/4885 |
| US-11730752-B2 | Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions | NNT, NAMPT, NMUR1 | KMT2A 2574/4885MEN1 1575/4885CALM1 600/4885 |
| US-20230090372-A1 | SMALL MOLECULE INHIBITORS OF VOLTAGE-GATED SODIUM CHANNEL 1.7 AND METHODS OF USING SAME | SCN7A, TRPC7, TRPV1 | KMT2A 3206/4885MEN1 3269/4885CALM1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.